Please login to the form below
lung cancer
This page shows the latest lung cancer news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
A phase 2 trial demonstrated an overall response rate of 57.7% in patients with non-small cell lung cancer. ... AZ and Daiichi Sankyo also announced promising results from its joint phase 1b trial assessing datopotamab deruxtecan (Dato-DXd) in patients
Latest news
-
AstraZeneca and Daiichi Sankyo announce results for lung cancer therapy
Initial results for the combination therapy – with Merck’s Keytruda – show an overall response rate of 37% in patients with non-small cell lung cancer. ... shown. Initial results from the TROPION-Lung02 study were presented at the International
-
Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy
In June this year, Tecentriq was approved by the European Commission for adults with non-small lung cancer who have a high risk of the disease recurring. ... benefit in various types of lung cancer, with six currently approved indications in countries
-
BeiGene announces positive phase 3 trial results for liver cancer treatment
There were more than 900, 000 new cases in 2020 of the most common type of primary liver cancer – unresectable hepatocellular carcinoma. ... BeiGene has already secured approval for the PD-1 inhibitor in China for the treatment of non-small cell lung
-
Sanofi and Innovent Biologics to develop oncology drugs for patients in China
lung cancer (NSCLC), gastric cancer and other cancers. ... s safety and effectiveness in a wide variety of cancer indications.
-
Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
This was compared with an intravenous (IV) infusion in cancer immunotherapy-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) for whom prior platinum therapy has failed. ... early-stage NSCLC, small cell lung cancer
More from news
Approximately 130 fully matching, plus 875 partially matching documents found.
Latest Intelligence
-
The promise of precision medicine
The most promising results seen to date show that genetic information has helped boost the survival rates of those suffering from advanced non-small-cell lung cancer by four to five
-
Successful product commercialisation: what can we learn from the rare disease setting?
With an increasing number of drug trials in crowded markets such as oncology (for example, in non-small cell lung cancer and multiple myeloma), understanding patient needs is not only critical
-
Growing evidence supports the important role of biosimilars in healthcare
The fatality rate was higher for patients with lung cancer and non-Hodgkin Lymphoma, at 15.7% and 9.4%, respectively. ... It also builds on previous studies demonstrating the cost-effectiveness of Zarxio as primary prophylaxis within patients with lung
-
Unlocking the potential of precision medicine in oncology
Targeted therapies. Furthermore, by following a similar trajectory in the treatment of non-small cell lung cancer (NSCLC), where we are studying specific alterations in the epidermal growth factor receptor (EGFR), ... We are following a similar approach
-
BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches
the other is designed to engage with any tumour-specific antigen, for example DLL3 in small-cell lung cancer, PSMA in prostate cancer and CLDN18.2 and MUC17 in gastric or ... T cells only become activated and proliferate, with the goal of staying
More from intelligence
Approximately 1 fully matching, plus 62 partially matching documents found.
Latest appointments
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
newly-diagnosed non-small cell lung cancer (NSCLC) patients.
-
Astellas bolsters oncology clinical development leadership
breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.
-
Iris Pauporté joins OSE Immunotherapeutics
Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research
-
Astellas promotes John Demaree
Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice
-
Merck appoints ex-Pfizer exec as global head of oncology
lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer.
More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest from PMHub
-
Ad tracking: the end of the road?
2. such as:. Health causes (e.g. ‘Lung cancer awareness’, ‘World Diabetes Day’, ‘Chemotherapy’).
-
Can tobacco companies really reinvent themselves as healthcare companies?
But can tobacco companies reinvent themselves as healthcare companies? Since smoking was linked to serious diseases such as lung cancer in the 1950s, health experts have been focused on influencing consumer ... Vectura has also been highly criticised for
-
Cancer: Beyond the Backlog
Not all cancers are equal, some have seen much more progress than others: for example brain, pancreatic, lung and oesaphageal cancer have all seen limited improvement in outcomes and there is ... We should be reinvigorating transformative ambitions for
-
Why you should feel optimistic about the future of healthcare
Precision medicines already exist; imatinib works to treat leukaemia only when the cancer cells have a particular genetic makeup, Sotorasib targets a specific mutation in people with lung cancer to halt
-
The heavy toll of COVID-19 on cancer patients
During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. ... The therapy works predominantly on non-small cell lung cancer. The NHS has also rolled out four chemo-buses which allowed patients to take part in therapy
More from PMHub
Approximately 3 fully matching, plus 20 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- UK government’s ‘science superpower’ ambitions to fail without clear plan, Lords committee warns
- How the Royal Society’s EiR programme can help to drive UK innovation
- Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
- Environment: where does the pharmaceutical industry stand?
- Moderna’s Omicron booster receives MHRA approval
- Lack of evidence for AstraZeneca’s COVID-19 vaccine says UK Department of Health
- NHS England outlines measures to boost capacity ahead of substantial winter pressures
- New research shows drug candidate may effectively treat antibiotic-resistant bacteria
- Sanofi and NIHR enrol first patient in immunisation study for RSV in infants
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- FDA approves Incyte’s Pemazyre as first targeted drug for bile duct cancer
- WHO, UNICEF and UNAIDS launch global alliance to end AIDS in children by 2030
- Creating content to trigger behaviour change
- Strategic commitment
PMHub
Dovetail
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...
Latest intelligence
- Environment: where does the pharmaceutical industry stand?
- ...
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
